公开(公告)号：EP2361251B1

公开(公告)日：2014-04-30

申请号：EP09781072.5

申请日：2009-07-24

申请人： Galapagos N.V.

发明人： MENET, Christel Jeanne Marie ,  VAN ROMPAEY, Luc Juliaan Corina ,  FLETCHER, Stephen Robert ,  BLANC, Javier ,  JOUANNIGOT, Nolwenn ,  HODGES, Alastair James ,  SMITS, Koen Kurt

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02

CPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/551 ,  C07D471/04

公开(公告)号：EP2361251A1

公开(公告)日：2011-08-31

申请号：EP09781072.5

申请日：2009-07-24

申请人： Galapagos N.V.

发明人： MENET, Christel Jeanne Marie ,  VAN ROMPAEY, Luc Juliaan Corina ,  FLETCHER, Stephen Robert ,  BLANC, Javier ,  JOUANNIGOT, Nolwenn ,  HODGES, Alastair James ,  SMITS, Koen Kurt

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02

CPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/551 ,  C07D471/04

摘要： [1,2,4]Triazolo[1,5-
a ]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6, transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.